Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the brand name of Eplerenone. The patent for Inspra expires for Pfizer on December 8, 2019. This double-blind and randomized trial included 1,012 patients who had an acute ST-segment elevation myocardial infarction, or STEMI. The patients in the study received between 25 and 50 milligrams of Eplerenone or a placebo, alongside optimal standard therapy. The patients who were dosed within the first 24 hours of symptom onset, especially those participants dosed within the first 12 hours of symptom onset, had a significant reduction in both heart failure and mortality as compared to the placebo group.
As a steroid nucleus-based mineralcorticoid receptor antagonist, Eplerenone is currently indicated in the United States to treat left ventricular systolic dysfunction, certain types of congestive heart failure and specific cases of hypertension. The European Union has also approved Eplerenone, along with best standard therapy, to reduce the risk of death from cardiovascular events in patients with NYHA class II heart failure. Japan has approved Eplerenone for the treatment of acute hypertension only. Patients who have known or prior cases of hyperkalemia should not be administered Eplerenone. People who have type 2 diabetes and microalbuminuria must be monitored if dosed with Eplerenone due to a heightened risk of renal insufficiency. Side effects reported by patients include dizziness, fatigue and mild diarrhea.
LGM Pharma provides Eplerenone for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.